Treatment recommendations depend on the severity and inflammatory activity

Due to its phenotypic heterogeneity and multifactorial pathogenesis, hidradenitis suppurativa is a complex disease that can be difficult to treat. Fortunately, research has achieved significant breakthroughs in the recent past, which is reflected in the fact that several biologics are now available and a number of drug candidates from the field of monoclonal antibodies and small molecules are being tested in trials. The further development of the therapy spectrum and other innovations are reflected in the recently published European S2k guideline.